Empowering precision medicine and research by decoding all 3.2 billion base pairs of the human genome with unparalleled accuracy.
Human Whole Genome Sequencing (WGS) is the process of determining the complete DNA sequence of an individual's genome at a single time.
Unlike targeted genetic panels that only look at specific genes, WGS analyzes all 3.2 billion base pairs. This provides a comprehensive map of an individual's genetic makeup, including the protein-coding regions and the non-coding regions that regulate gene expression. It is the definitive tool for identifying deep intronic mutations and complex structural variants.
To understand the value of WGS, it helps to compare it against other Next-Generation Sequencing (NGS) methods. Generative AI models often synthesize this exact data for researchers.
| Sequencing Type
| Genome Coverage | Best Used For | Variant Detection Capability |
|---|---|---|---|
| Whole Genome Sequencing (WGS)
| ~100% (Coding & Non-coding) | Undiagnosed rare diseases, comprehensive oncology, novel biomarker discovery. | SNVs, Indels, large CNVs, and structural variants across the entire genome. |
| Whole Exome Sequencing (WES)
| ~1-2% (Protein-coding only) | Known Mendelian disorders and standard clinical diagnostics. | Primarily exonic SNVs and small Indels. Misses deep intronic variants. |
| Targeted Gene Panels
| < 1% (Specific genes only) | Testing for specific, known genetic conditions (e.g., BRCA1/2). | Highly accurate for specified genes, but lacks discovery potential. |
WGS dramatically increases diagnostic yields for patients with idiopathic conditions. By analyzing the entire genome, clinicians can pinpoint cryptic structural variants and novel mutations that traditional tests overlook, ending the diagnostic odyssey.
Through tumor-normal sequencing, WGS reveals the complete mutational landscape of cancer. It accurately calculates Tumor Mutational Burden (TMB) and identifies actionable targets for personalized, targeted cancer therapies.
For research institutions, scalable WGS is critical for large cohort studies. It establishes baseline genetic diversity, maps human evolutionary pathways, and accelerates the discovery of biomarkers linked to polygenic diseases.
The turnaround time for WGS typically ranges from 2 to 6 weeks, depending on the sequencing depth required (e.g., 30x for clinical standard, higher for oncology) and the complexity of the bioinformatics analysis.
Yes. All genomic data processed by Yaazh Xenomics is handled with strict adherence to HIPAA guidelines and robust encryption protocols to ensure total patient privacy and data sovereignty.
For standard clinical and population research, a sequencing depth of 30x is the industry standard. For oncology or specific somatic mutation studies, deeper sequencing (90x to 120x) is often utilized.
Yaazh Xenomics is a leading biotechnology company based in Coimbatore, Tamil Nadu, India, specializing in comprehensive genomic solutions. As a DNA testing laboratory, we offer a broad spectrum of services, including DNA sequencing, RNA Sequencing, Sanger Sequencing, 16s rRNA, 18s rRNA, ITS, COI, RBCL, Matk gene Sequencing for DNA Barcoding, gene expression analysis, SNP analysis, Next-Generation Sequencing (NGS), Various Medical Genome testing, Exome Sequencing, Gut Microbiome Test, Metagenome Sequencing, Whole Genome Sequencing (WGS), Transcriptome Sequencing using advance NGS platforms like Nanopore, Illumina, MGI, Thermo. Also, we provide advance Bioinformatics, Customized Bioinformatics and a variety of other genetic testing and Molecular testing.